MetaVia is trading 5.42% down in pre-market at $1.57, amid broader risk-off sentiment pressuring equities.
- MetaVia declined 5.14% to $1.66 on September 11.
- No credible September 14 company-specific announcement, earnings release, analyst action, or regulatory catalyst was identified.
- The latest identifiable company news was September 9 preclinical DA-1726 data; Nasdaq futures are also under pressure.